Dr. Levine on the PARP Inhibitor Landscape for Ovarian Cancer

Douglas A. Levine, MD
Published: Friday, Jul 07, 2017



Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the PARP inhibitor landscape for patients with ovarian cancer.

The PARP inhibitor landscape is getting more complex, states Levine. A main question that still faces physicians is when to use PARP inhibitors and for which types of patients.

Some of the agents are indicated only for those patients who have a germline and/or somatic mutation. Nirparib has an indication for all-comers, yet the effect of the drug is much less when an patient does not have a BRCA mutation, explains Levine.
 


Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the PARP inhibitor landscape for patients with ovarian cancer.

The PARP inhibitor landscape is getting more complex, states Levine. A main question that still faces physicians is when to use PARP inhibitors and for which types of patients.

Some of the agents are indicated only for those patients who have a germline and/or somatic mutation. Nirparib has an indication for all-comers, yet the effect of the drug is much less when an patient does not have a BRCA mutation, explains Levine.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x